FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MESSINA RICHARD 		2. Issuer Name and Ticker or Trading Symbol

JUNIPER PHARMACEUTICALS INC [ JNP ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O JUNIPER PHARMACEUTICALS INC., 33 ARCH STREET SUITE 3110 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/14/2018
(Street)

BOSTON, MA 02110
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/14/2018     D (1)    13657   (2) D $11.50   0   D    
Common Stock   8/14/2018     D (1)    250   D $11.50   0   I   See Footnote   (3)
Common Stock   8/14/2018     D (1)    250   D $11.50   0   I   See Footnote   (4)
Common Stock   8/14/2018     D (1)    250   D $11.50   0   I   See Footnote   (5)
Common Stock   8/14/2018     D (1)    8000   D $11.50   0   I   See Footnote   (6)
Common Stock   8/14/2018     D (1)    9700   D $11.50   0   I   See Footnote   (7)
Common Stock   8/14/2018     D (1)    41000   D $11.50   0   I   See Footnote   (8)
Common Stock   8/14/2018     D (1)    14500   D $11.50   0   I   See Footnote   (9)
Common Stock   8/14/2018     D (1)    2001   D $11.50   0   I   See Footnote   (10)
Common Stock   8/14/2018     D (1)    28000   D $11.50   0   I   See Footnote   (11)
Common Stock   8/14/2018     D (1)    6250   D $11.50   0   I   See Footnote   (12)
Common Stock   8/14/2018     D (1)    875   D $11.50   0   I   See Footnote   (13)
Common Stock   8/14/2018     D (1)    100000   D $11.50   0   I   See Footnote   (14)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
(2)  Includes 5,625 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 5,625 restricted stock units was cancelled in exchange for the Offer Price.
(3)  Shares held by Richard Messina CF Jacqueline Messina UTMA.
(4)  Shares held by Richard Messina CF Carolyn Messina UTMA.
(5)  Shares held by Richard Messina CF Madeline Messina UTMA.
(6)  Shares held by Equity TR Co TTEE FBO Pamela Brocious SEP.
(7)  Shares held by Steve A. Sanders and Partners.
(8)  Shares held by Citistaffing LLC Profit Sharing.
(9)  Shares held by Summit Capital Associates.
(10)  Shares held by Benchmark Pellinore Group.
(11)  Shares held by SCA Retirement Plan DTD 1/1/91.
(12)  Shares held by Pamela Brocious M/P PEN PL.
(13)  Shares held by SCA Money Purchase Plan DTD 1/1/94 Attn Richard Messina.
(14)  Shares held by The Benchmark Company LLC - Investment Purposes.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MESSINA RICHARD
C/O JUNIPER PHARMACEUTICALS INC.
33 ARCH STREET SUITE 3110
BOSTON, MA 02110 		X



Signatures
/s/ Jeffrey Young, Attorney-in-Fact 8/15/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Juniper Pharmaceuticals, Inc. Charts.
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Juniper Pharmaceuticals, Inc. Charts.